谷氨酸受体2基因多态性与儿童癫癎的相关性

Association between glutamate receptor 2 polymorphisms and epilepsy in children

摘要:

目的 探讨我国中部地区汉族人群中谷氨酸受体2(GRIK2)基因两个SNP位点rs9390754和rs4840200的多态性与儿童癫癎遗传易感性的关系。方法 利用病例对照研究方法,选取来自我国中部地区的284例癫癎患儿(包括132例难治性癫癎)以及315例正常体检儿童(对照组)作为研究对象。利用限制性片段长度多态性(PCR-RFLP)的方法测定SNP位点rs9390754和rs4840200的多态性分布,并比较组间的基因型频率的差异。结果 癫癎组儿童SNP位点(rs9390754)的基因型(GG、GA、AA)频率与对照组相比差异有统计学意义(P = 0.016),等位基因频率差异也有统计学意义(P = 0.002)。而SNP位点(rs4840200)基因型(CC、CT、TT)频率以及等位基因频率与对照组相比差异均无统计学意义。难治性癫癎亚组SNP位点(rs4840200)C等位基因频率高于非难治性癫癎亚组(OR = 1.435, 95%CI: 1.021~2.016, P = 0.037)。结论 我国中部地区汉族人群GRIK2基因SNP位点(rs9390754)的多态性与癫癎的易感性相关,而SNP位点(rs4840200)的C等位基因可能是癫癎患儿发生耐药的遗传学危险因素。

Abstract:

Objective To investigate the association between two single nucleotide polymorphisms (SNPs), rs9390754 and rs4840200, in the glutamate receptor 2 (GRIK2) gene and the genetic susceptibility to epilepsy (EP) in the Han population in Central China. Methods A case-control study was performed in 284 EP children (including 132 children with refractory epilepsy) and 315 normal children from Central China. Polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) was used to determine the genotypes of the two SNPs rs9390754 and rs4840200. The genotype frequency was compared between groups. Results The frequencies of GG, GA, and AA genotypes of SNP rs9390754 showed a significant difference between the EP and normal control groups (P = 0.016). The allele frequency also showed a significant difference between the two groups (P = 0.002). The frequencies of CC, CT, and TT genotypes of SNP rs4840200 and allele frequency showed no significant differences between the two groups. The C allele frequency of SNP rs4840200 in the refractory EP subgroup was significantly higher than in the non-refractory EP subgroup (OR = 1.435, 95% CI: 1.021-2.016, P = 0.037). Conclusions In the Han population in Central China, the polymorphisms of SNP rs9390754 in the GRIK2 gene may be associated with EP susceptibility, and the C allele of SNP rs4840200 may be a genetic risk factor for the development of drug resistance in children with EP.